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Josep Rodés-Cabau, MDA 66-year old man with severe functional mitralregurgitation (Figure 1A) secondary to chronicischemic cardiomyopathy (previous myocar-
dial infarction and coronary artery bypass grafting)
and advanced heart failure (left ventricular ejection
fraction: 25%; New York Heart Association [NYHA]
functional class III) was considered to be at very high
surgical risk and was ﬁnally accepted by the Heart
Team for transcatheter mitral valve implantation
(TMVI) with the FORTIS transcatheter valve (Edwards
Lifesciences, Irvine, California) (Figures 1B and 1C).
The procedure was performed using previously
described techniques (1). In brief, the valve was
inserted in the left ventricular cavity using a 40-
French delivery catheter through the left ventricular
apex. The valve prosthesis paddles were unsheathed
to capture the native mitral leaﬂets at the A2-P2 level
(Online Video 1). After conﬁrmation of native mitral
leaﬂet capture, full deployment of the valve sys-
tem was successfully performed (Figure 1D, Online
Video 2).
After valve deployment, transesophageal echocar-
diography (TEE) images revealed the presence of a
mild to moderate perivalvular leak at the level of the
posteromedial commissure (Figure 1E, Online Video 3;
Figure 1F, Online Video 4). However, cardiac magnetic
resonance (CMR) showed the absence of any residual
leak (Figure 1G, Online Video 5), and multislice
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(Figures 1H and 1I, Online Video 6). The post-
procedural period was uneventful, and the patient
was discharged 5 days after the intervention. At 1-
month follow-up, the patient was in NYHA func-
tional class I, and TEE showed a minimal “pseudo
leak” (Online Video 7) and a mean transvalvular
gradient of 3 mm Hg.
TMVI has recently emerged as a new option for the
treatment of mitral regurgitation. An accurate evalu-
ation of the presence of residual leaks remains of
maximal importance for determining device perfor-
mance and success. This report shows that the
interpretation of residual leaks after TMVI may be
challenging. We hypothesize that the relationship
between the captured leaﬂets (A2-P2) and the free
leaﬂets (A3-P3) generated an eccentric turbulent ﬂow
between the native leaﬂets and the valve prosthesis
that resulted in an image suggestive of paravalvular
leak. However, the eccentric jet did not extend into
the atrium (“pseudo leak”), as further conﬁrmed by
CMR, and tended to disappear over time, probably
due to new tissue growth covering the paddles of the
valve prosthesis.
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FIGURE 1 Transcatheter Mitral Valve Implantation With the FORTIS Device (Pre-Procedural, Procedural, and Post-Procedural Images)
(A) Four-chamber transthoracic echocardiogram view showing severe functional mitral regurgitation due to restriction of the posterior leaﬂet
and tethering of subvalvular apparatus. (B, C) The FORTIS transcatheter heart valve system (Edwards Lifesciences) consists of a nitinol stent
frame including 2 paddles (black and blue arrows) and a valve with 3 leaﬂets of bovine pericardial tissue sutured inside. (D) Fluoroscopic
images (right anterior oblique projection) showing the FORTIS prosthesis deployed in the mitral annulus (Online Video 2). (E) Transesophageal
echocardiography images (45 short-axis view) showing an eccentric turbulent jet in the posteromedial commissure between the prosthesis and
the free portion of the native mitral leaﬂets (red arrow) (Online Video 3). (F) Transesophageal echocardiography images (0 long-axis view)
showing a turbulent jet generated in the septal wall (red arrow) (Online Video 4). (G) Cardiac magnetic resonance in the end-systolic phase. No
signiﬁcant mitral regurgitation was found using both a direct quantiﬁcation method (mitral regurgitant volume: 2 ml; mitral regurgitant
fraction: 4%) and indirect quantiﬁcation method (mitral regurgitant volume: 2 ml; mitral regurgitant fraction: 2%; left ventricular stroke
volume: 89 ml; left ventricular ejection fraction: 28%; aortic antegrade volume: 87 ml; aortic regurgitant volume: 1 ml). We observed an
optimal position of the prosthesis in the mitral annulus. The “pseudo leak” seems to be generated in the virtual space (white star) between the
native leaﬂets captured by the paddles (arrows) and the atrial part of the prosthesis (Online Video 5). (H) Left superior view of 3-dimensional
multislice computed tomography showing the FORTIS valve system correctly positioned in the mitral annulus (Online Video 6). (I) Multislice
computed tomography images showing an optimal clearance in the left ventricular outﬂow tract (red double-headed arrow). a ¼ left atrial
side; V ¼ left ventricular side; Ao ¼ aorta; PV ¼ pulmonary vein. The black arrow indicates posterior paddle; the blue arrow indicates anterior
paddle; the red arrow indicates pseudo perivalvular leak; the white star indicates virtual space between the native leaﬂets captured by the
paddles and the atrial side of the prosthesis; the red double-headed arrow indicates left ventricular outﬂow tract clearance. See also
Online Videos 1 and 7.
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